Clinical Trials
17 trialsNCT06980038 2026-06-01
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06855212 2026-05-20
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06769698 2026-05-06
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT03916627 2026-04-06
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT04722523 2026-03-30
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04862650 2026-02-10
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT06923761 2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT04916002 2025-12-05
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
Phase 2 Terminated
NCT04305795 2025-06-19
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Rakuten Medical, Inc.
Phase 1/2 Active not recruiting
NCT04291105 2025-03-26
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad, Inc.
Phase 2 Recruiting
NCT04465487 2025-02-24
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
Regeneron Pharmaceuticals
Phase 1 Terminated
NCT04398524 2024-01-16
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT03669718 2023-12-29
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC
ISA Pharmaceuticals
Phase 2 Unknown
NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT04831450 2022-08-04
Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Miami
Phase 2 Withdrawn